Vanderbilt receives $1M grant to fund immunotherapy research in CRC

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.

November 15, 2024

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Researchers from the USC Norris Comprehensive Cancer Center found evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases. The study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer.

November 15, 2024

Vol.50 No.43

Drugs & Targets

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced a collaborative agreement with Thermo Fisher Scientific Inc. through its subsidiary Life Technologies Corporation.

November 15, 2024

Vol.50 No.43

In Brief

Cathy Eng named associate director of strategic relations and research partnerships at Vanderbilt-Ingram

Cathy Eng, David H. Johnson Professor of Surgical and Medical Oncology, was named associate director of strategic relations and research partnerships for Vanderbilt-Ingram Cancer Center.

October 18, 2024

Vol.50 No.39

In Brief

UCLA researchers receive $3M NIH grant for CRC screening follow-up in underserved communities

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center were awarded a $3 million grant from NIH to improve follow-up care for colorectal cancer screening in underserved populations.

October 04, 2024

Vol.50 No.37

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

YOU MAY BE INTERESTED IN

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

Cathy Eng named associate director of strategic relations and research partnerships at Vanderbilt-Ingram

UCLA researchers receive $3M NIH grant for CRC screening follow-up in underserved communities

Renew today!

Subscriber content

Login